The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Tregs and rethinking cancer immunotherapy
Open accessAbstract
Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Recent work demonstrates that one reason for the lack of tumor rejection is that tumors actively defeat host immunity. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. CD4+CD25+ Tregs are one mechanism of tumor-driven immune evasion that provide prototypical targets for testing novel anticancer treatment strategies within the newer paradigm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationThe Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature Reviews Immunology · doi:10.1038/nri1032 · Cited by 1,323
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Self-citationGhiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Foxp3-dependent programme of regulatory T-cell differentiation
Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,135
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
COLEY, W. B. (1893) · The American Journal of the Medical Sciences · doi:10.1097/00000441-189305000-00001 · Cited by 995
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
Levings, M. K., Sangregorio, R., & Roncarolo, M.-G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1295 · Cited by 967
Cytotoxic T-Cell Immunity to Influenza
McMichael, A. J., Gotch, F. M., Noble, G. R., & Beare, P. A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090103 · Cited by 927
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression
Wan, Y. Y., & Flavell, R. A. (2007) · Nature · doi:10.1038/nature05479 · Cited by 854
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748
Self-citationFoxp3 occupancy and regulation of key target genes during T-cell stimulation
Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S., Polansky, J. K., MacIsaac, K. D., Levine, S. S., Fraenkel, E., von Boehmer, H., & Young, R. A. (2007) · Nature · doi:10.1038/nature05478 · Cited by 724
Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response
Taniguchi, M., Harada, M., Kojo, S., Nakayama, T., & Wakao, H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141057 · Cited by 669
Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 655
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
Self-citationIL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Ahmadzadeh, M., & Rosenberg, S. A. (2006) · Blood · doi:10.1182/blood-2005-06-2399 · Cited by 632
Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells
Lim, H. W., Hillsamer, P., Banham, A. H., & Kim, C. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4180 · Cited by 600
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level
Roncador, G., Brown, P. J., Maestre, L., Hue, S., Martínez-Torrecuadrada, J. L., Ling, K.-L., Pratap, S., Toms, C., Fox, B. C., Cerundolo, V., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526189 · Cited by 592
Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter
Wan, Y. Y., & Flavell, R. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501701102 · Cited by 576
Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment
Polanczyk, M. J., Carson, B. D., Subramanian, S., Afentoulis, M., Vandenbark, A. A., Ziegler, S. F., & Offner, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2227 · Cited by 521
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., & Wang, R.-F. (2004) · Immunity · doi:10.1016/s1074-7613(03)00359-5 · Cited by 515
Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet, A. G., Muller-Holzner, E., Deibl, M., Gastl, G., Gunsilius, E., & Marth, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1244 · Cited by 511
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484
Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q., Lonning, S., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453
Álvaro, T., Lejeune, M., Salvadó, M. T., Bosch, R., García, J. F., Jaén, J., Banham, A. H., Roncador, G., Montalbán, C., & Piris, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1869 · Cited by 450
Jarnicki, A. G., Lysaght, J., Todryk, S., & Mills, K. H. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.896 · Cited by 445
FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis
Kobayashi, N., Hiraoka, N., Yamagami, W., Ojima, H., Kanai, Y., Kosuge, T., Nakajima, A., & Hirohashi, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2363 · Cited by 431
Pardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Tumor-induced immune dysfunction: the macrophage connection
Elgert, K. D., Alleva, D. G., & Mullins, D. W. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.3.275 · Cited by 426
Yang, Z.-Z., Novak, A. J., Stenson, M. J., Witzig, T. E., & Ansell, S. M. (2006) · Blood · doi:10.1182/blood-2005-08-3376 · Cited by 420
Regulatory T cells under scrutiny
François Bach, J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1026 · Cited by 413
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Self-citationRole Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346
Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M., & Dhodapkar, K. M. (2006) · Blood · doi:10.1182/blood-2006-03-011353 · Cited by 311
Dendritic cells: On the move from bench to bedside
Nestle, F. O., Banchereau, J., & Hart, D. (2001) · Nature Medicine · doi:10.1038/89863 · Cited by 287
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
Silverstein, A. M. (1989) · doi:10.1016/b978-0-12-370586-0.x0001-7 · Cited by 286
Terabe, M., Swann, J., Ambrosino, E., Sinha, P., Takaku, S., Hayakawa, Y., Godfrey, D. I., Ostrand-Rosenberg, S., Smyth, M. J., & Berzofsky, J. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051381 · Cited by 283
Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Zhou, G., Drake, C. G., & Levitsky, H. I. (2006) · Blood · doi:10.1182/blood-2005-07-2737 · Cited by 272
Immune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 265
Mahic, M., Yaqub, S., Johansson, C. C., Taskén, K., & Aandahl, E. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.246 · Cited by 248
Mahnke, K., Schönfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T., Johnson, T. S., Storn, V., Schallenberg, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22617 · Cited by 244
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Dysfunctional T regulatory cells in multiple myeloma
Prabhala, R. H., Neri, P., Bae, J. E., Tassone, P., Shammas, M. A., Allam, C. K., Daley, J. F., Chauhan, D., Blanchard, E., Thatte, H. S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3101 · Cited by 239
Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential
Barnett, B., Kryczek, I., Cheng, P., Zou, W., & Curiel, T. J. (2005) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2005.00330.x · Cited by 233
Self-citationLi, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., & Jooss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 232
Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S., & Katsanis, E. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0160-8 · Cited by 225
Crosnier, J., Jungers, P., Couroucé, A., Laplanche, A., Benhamou, E., Degos, F., Lacour, B., Prunet, P., Cerisier, Y., & Guesry, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92679-9 · Cited by 214
Steitz, J., Brück, J., Lenz, J., Knop, J., & Tüting, T. (2001) · PubMed · Cited by 214
Grauer, O. M., Nierkens, S., Bennink, E., Toonen, L. W. J., Boon, L., Wesseling, P., Sutmuller, R. P. M., & Adema, G. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22607 · Cited by 212
Tanaka, H., Tanaka, J., Kjaergaard, J., & Shu, S. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00003 · Cited by 206
Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines
Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Ménard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jèse, G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2722 · Cited by 200
Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 195
Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S. K., Monos, D. S., Peritt, D., Marincola, F. M., Cai, D., et al. (2002) · PubMed · Cited by 181
Gene segment selection in V(D)J recombination: accessibility and beyond
Krangel, M. S. (2003) · Nature Immunology · doi:10.1038/ni0703-624 · Cited by 176
Nishikawa, H., Jäger, E., Ritter, G., Old, L. J., & Gnjatic, S. (2005) · Blood · doi:10.1182/blood-2005-02-0607 · Cited by 173
LEGIONNAIRES' DISEASE RELATED TO GASTRIC LAVAGE WITH TAP WATER
Dournon, E., Bure, A., Desplaces, N., Carette, M. F., & Mayaud, C. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91837-2 · Cited by 161
Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity
Nair, S. K., Boczkowski, D., Faßnacht, M., Pisetsky, D. S., & Gilboa, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2903 · Cited by 150
CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Javia, L. R., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200301000-00009 · Cited by 135
Restraining the V(D)J recombinase
Roth, D. B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1152 · Cited by 134
DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma
Foss, F. M. (2000) · Clinical Lymphoma · doi:10.3816/clm.2000.n.009 · Cited by 126
Knutson, K. L., Dang, Y., Lu, H., Lukas, J. L., Almand, B., Gad, E. A., Azeke, E., & Disis, M. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.84 · Cited by 126
Nonacs, R. M., Humborg, C., Tam, J. P., & Steinman, R. M. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.2.519 · Cited by 125
TGF Beta Inhibition for Cancer Therapy
Saunier, E. F., & Akhurst, R. J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778742460 · Cited by 114
FOXP3 and NFAT: Partners in Tolerance
Rudensky, A. Y., Gavin, M. A., & Zheng, Y. (2006) · Cell · doi:10.1016/j.cell.2006.07.005 · Cited by 110
Interleukin-10: a cytokine used by tumors to escape immunosurveillance
Salazar‐Onfray, F. (1999) · Medical Oncology · doi:10.1007/bf02785841 · Cited by 104
Lack of Suppressive CD4+CD25+FOXP3+ T Cells in Advanced Stages of Primary Cutaneous T-Cell Lymphoma
Tiemessen, M. M., Mitchell, T. J., Hendry, L., Whittaker, S. J., Taams, L. S., & John, S. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700371 · Cited by 99
Berd, D., & Mastrangelo, M. J. (1987) · PubMed · Cited by 96
Bursuker, I., & North, R. J. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.159.5.1312 · Cited by 88
Pardoll, D. M. (2001) · Nature · doi:10.1038/35082676 · Cited by 87
Kudo‐Saito, C., Schlom, J., Camphausen, K. A., Coleman, C. N., & Hodge, J. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2237 · Cited by 84
Unique Tumor-Specific Antigens
Schreiber, H. W., Ward, P. L., Rowley, D. A., & Stauss, H. J. (1988) · Annual Review of Immunology · doi:10.1146/annurev.iy.06.040188.002341 · Cited by 79
Biologic and Immunologic Therapies for Ovarian Cancer
Berek, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.517 · Cited by 69
Rüter, J., Barnett, B. G., Kryczek, I., Brumlik, M. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2009) · Frontiers in bioscience · doi:10.2741/3338 · Cited by 66
Self-citationImmune suppression by tumor-specific CD4+ regulatory T-cells in cancer
Wang, R. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.009 · Cited by 65
Regulatory T-cell development: is Foxp3 the decider?
Curiel, T. J. (2007) · Nature Medicine · doi:10.1038/nm0307-250 · Cited by 57
Self-citationRegulatory T cells and Toll-like receptors in tumor immunity
Wang, R., Peng, G., & Wang, H. Y. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.01.008 · Cited by 56
Chen, A., Liu, S., Park, D. S., Kang, Y., & Zheng, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2622 · Cited by 55
Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation
Spiotto, M. T., Fu, Y., & Schreiber, H. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.09.018 · Cited by 54
Stauss, H. J., Waes, C. V., Fink, M. A., Starr, B., & Schreiber, H. W. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.5.1516 · Cited by 48
New tools to identify regulatory T cells
Graça, L. (2005) · European Journal of Immunology · doi:10.1002/eji.200526303 · Cited by 25
Yang, R., Maes, H., Romanelli, M. M. C., Dellner, F., Wen, T., & Kiessling, R. W. (1998) · Cytokine · doi:10.1006/cyto.1998.0357 · Cited by 21
Immunologic principles and immunotherapeutic approaches in ovarian cancer
Knutson, K. L., Curiel, T. J., Salazar, L. G., & Disis, M. L. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00064-9 · Cited by 19
Self-citation
Cited by
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
Metadata
- Authors
- Curiel, T. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1167-1174
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2131778873
- Cited by
- 547
- References
- 122
- FWCI
- 18.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.